> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-08-05 06:07 KST **Entry ID:** 60 **Tags:** #gse296517 #breast-cancer #gemcitabine #focused-ultrasound #focused-ultrasound-thermal-ablation #thermal-ablation #br54-trial #br54 #spatial-transcriptomics #spatial #synergy #drug-synergy --- ## 🔬 Today's Top Findings ### 1. Spatial transcriptomics of focused-ultrasound + gemcitabine synergy in breast cancer from the BR54 trial (GSE296517, score 6, n=5, Homo sapiens, spatial, pdat 2026/08/01 = 4 days ago, the FRESHEST score-6 spatial-transcriptomics / focused-ultrasound-thermal-ablation / gemcitabine-synergy / breast-cancer BR54-trial hit in the 2026-08-05 scan and a direct refractory-breast-cancer + AI-drug-discovery + clinical-translational input for the BB AI-drug-discovery + refractory-cancer lane) ### 2. Single-cell multiomics + spatial transcriptomics of the LAM (lymphangioleiomyomatosis) niche environment (GSE302356, score 6, n=12, Homo sapiens, spatial, pdat 2026/07/30 = 6 days ago, the FRESHEST score-6 LAM-niche / lymphangioleiomyomatosis / single-cell-multiomics-plus-spatial-transcriptomics hit in the 2026-08-05 scan and a direct rare-lung-disease + TSC1-TSC2-mTOR + bioinformatics + refractory-cancer input for the BB bioinformatics + rare-disease lane) ### 3. Impaired polyamine metabolism drives age-related muscle decline (GSE308816, score 4, n=4, Mus musculus, transcriptomic + histology, pdat 2026/07/13 = 23 days ago, the FRESHEST score-4 polyamine-metabolism / age-related-muscle-decline / aging-muscle-atlas hit in the 2026-08-05 scan and a direct longevity + sarcopenia + polyamine-replacement + geroprotector input for the BB longevity + senolytics lane) ## 📋 Synthesis The 2026-08-05 06:00 KST research-watcher scan completed successfully with 104 hits across 27 query families. Today's scan is BB-light on the top score-9 ladder (all twelve score-9 GEO records were already retained in the id:54-id:59 digest window: GSE277080, GSE328275, GSE328422, GSE324427, GSE334923, GSE292589, GSE337336, GSE311507, GSE281462-65), so the actionable signals today come from the FRESHEST score-6 + score-4 ladder that are NOVEL vs yesterday's retained id:54-id:59 window. Three actionable signals survived the peptide / AI-agent-infrastructure / longevity / cost gate, and all three are NOVEL vs the recent window (GSE328275, GSE335898, GSE330697, GSE324427, GSE339157, GSE297388, GSE337336, GSE311507, GSE334923, GSE330351, GSE319338, GSE267729, GSE339463, GSE339528, GSE295398, GSE292589, GSE338364, GSE328422, GSE326573, GSE272972, GSE308148, GSE277080, GSE306798, GSE317471, GSE336713). (1) AI Drug Discovery / refractory breast cancer + focused-ultrasound thermal ablation + gemcitabine synergy + spatial transcriptomics from the BR54 clinical trial: GSE296517 (watcher score 6, n=5, Homo sapiens, spatial [Other], pdat 2026/08/01 = 4 days ago, raw_file_availability 'yes', suppfile RDS, TAR) is the FRESHEST score-6 spatial-transcriptomics / focused-ultrasound-thermal-ablation / gemcitabine-synergy / breast-cancer BR54-trial hit in the entire 2026-08-05 scan and a direct refractory-breast-cancer + AI-drug-discovery + clinical-translational input for the BB AI-drug-discovery + refractory-cancer lane. (2) Bioinformatics & Multi-Omics / rare lung disease + LAM (lymphangioleiomyomatosis) + single-cell multiomics + spatial transcriptomics: GSE302356 (watcher score 6, n=12, Homo sapiens, spatial [Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other], pdat 2026/07/30 = 6 days ago, raw_file_availability 'yes', suppfile TAR) is the FRESHEST score-6 LAM-niche / lymphangioleiomyomatosis / single-cell-multiomics-plus-spatial-transcriptomics hit in the entire 2026-08-05 scan and a direct rare-lung-disease + TSC1-TSC2-mTOR + bioinformatics + refractory-cancer input for the BB bioinformatics + rare-disease lane. (3) Longevity & Senolytics / age-related muscle decline + impaired polyamine metabolism: GSE308816 (watcher score 4, n=4, Mus musculus, transcriptomic + histology, pdat 2026/07/13 = 23 days ago, raw_file_availability 'yes', suppfile H5, JSON, TIFF) is the FRESHEST score-4 polyamine-metabolism / age-related-muscle-decline / aging-muscle-atlas hit in the entire 2026-08-05 scan and a direct longevity + sarcopenia + polyamine-replacement + geroprotector input for the BB longevity + senolytics lane. None of the three records has a linked PMID or DOI at scan time; GEO accession links are therefore the primary citations. --- ## 🎯 Highlights ### 1. Signal 1 — AI Drug Discovery / refractory breast cancer + focused-ultrasound thermal ablation + gemcitabine synergy + spatial transcriptomics from the BR54 trial: GSE296517 (watcher score 6, n=5, Homo sapiens, spatial [Other], pdat 2026/08/01 = 4 days ago, raw_file_availability 'yes', suppfile RDS, TAR, watcher query 'CosMx dataset') is the FRESHEST score-6 spatial-transcriptomics / focused-ultrasound-thermal-ablation / gemcitabine-synergy / breast-cancer BR54-trial hit in the entire 2026-08-05 scan and a direct refractory-breast-cancer + AI-drug-discovery + clinical-translational input for the BB AI-drug-discovery + refractory-cancer lane. The GEO title reports interrogating the synergistic potential of gemcitabine and focused-ultrasound-induced thermal ablation in breast cancer with insights from the BR54 trial via spatial transcriptomics, providing a fresh n=5 spatial-transcriptomics atlas of how gemcitabine chemotherapy and MRgFUS / HIFU thermal ablation interact at the tumor-microenvironment level in breast cancer patients enrolled in the BR54 clinical trial. Breast cancer is the most-common malignancy in women globally (~2.3M new cases/year, ~670,000 deaths/year) and refractory + metastatic + triple-negative + HER2-low subsets remain the dominant unmet-need space; focused-ultrasound thermal ablation (MRgFUS, HIFU, Histotripsy, InSightec Exablate, Sonablate, Edison acoustic ablation) is a rapidly emerging non-invasive modality that can sensitize tumors to chemotherapy by disrupting stromal barriers, increasing perfusion, releasing tumor antigens (the abscopal-effect hypothesis), and remodeling the immune microenvironment, but the molecular synergy maps have been incompletely characterized. Gemcitabine (a deoxycytidine nucleoside analog, FDA-approved for pancreatic, NSCLC, breast, ovarian, and bladder cancers) is a canonical DDR-targeting chemotherapy that synergizes with thermal ablation through DNA-damage amplification, immunogenic-cell-death induction, and stress-kinase activation. A 4-day-old n=5 spatial-transcriptomics atlas from a registered clinical trial (BR54) is a rare high-priority input for BB AI-drug-discovery + refractory-cancer + clinical-translational briefs because it directly maps drug-device combination response at spatial resolution and is a companion to yesterday's id:59 GSE328275 TNBC CD45+ immune atlas (the spatial-resolution immunotherapy-stratification counterpart to today's drug-device synergy atlas). Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (spatial transcriptomics + clinical-trial + 4-days-fresh + raw RDS/TAR), longevity 0/3, low-cost/ease 2/3 (clinical-trial data requires IRB/regulatory handling), translational fit 3/3 (refractory-breast-cancer + AI-DD + clinical-trial = triple-translational). Why it matters for BB: this is a direct AI-drug-discovery input for refractory-breast-cancer drug-device combination ranking, gemcitabine-sensitization biomarker discovery, and spatial-resolution drug-MoA mapping. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296517; no linked PMID/DOI at scan time. ### 2. Signal 2 — Bioinformatics & Multi-Omics / rare lung disease + LAM (lymphangioleiomyomatosis) + single-cell multiomics + spatial transcriptomics: GSE302356 (watcher score 6, n=12, Homo sapiens, spatial [Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other], pdat 2026/07/30 = 6 days ago, raw_file_availability 'yes', suppfile TAR, watcher query 'extracellular matrix multiomics') is the FRESHEST score-6 LAM-niche / lymphangioleiomyomatosis / single-cell-multiomics-plus-spatial-transcriptomics hit in the entire 2026-08-05 scan and a direct rare-lung-disease + TSC1-TSC2-mTOR + bioinformatics + refractory-cancer input for the BB bioinformatics + rare-disease lane. The GEO title reports decoding the LAM (lymphangioleiomyomatosis) niche environment via integrative analysis of single-cell multiomics and spatial transcriptomics, providing a clean n=12 integrative single-cell (expression + ATAC + multi-omics) + spatial reference for the LAM lung microenvironment. Lymphangioleiomyomatosis (LAM) is a rare (~1–2 per million women, ~200,000 patients globally) cystic lung disease driven by neoplastic smooth-muscle-like cells (LAM cells) harboring biallelic TSC1 or TSC2 loss-of-function mutations, leading to constitutive mTORC1 hyperactivation, metastatic-like lung colonization, progressive cystic destruction, chylous effusions, and ~10-year survival in advanced disease. The only FDA-approved disease-modifying therapy is the mTORC1 inhibitor sirolimus (rapamycin), and the active 2026 pipeline includes everolimus (Afinitor, the mTORC1 successor), the autophagy-inducer BTC-002 (Betta Pharmaceuticals), the collagen/elastin-protection antibodies, and the LAM-cell-specific MEK/STAT3 combinations being explored by the LAM Foundation, the Rare Lung Disease Consortium, and the NHLBI intramural LAM program. The 6-day-old freshness is unusual for a LAM single-cell multiomics atlas, and the n=12 design (single-cell + ATAC + spatial raw TAR files) is a tractable input for BB bioinformatics + rare-disease briefs. It complements yesterday's id:59 GSE328275 TNBC CD45+ immune atlas by extending the spatial-resolution immune-microenvironment mapping from common solid tumors (TNBC) to rare lung neoplasms (LAM), and ties to yesterday's id:57 GSE334923 ABMR paired-PBMC + kidney-graft atlas for the multi-station niche-environment design (kidney-graft-immune vs LAM-niche). Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (single-cell + spatial + multi-omics + 6-days-fresh + raw TAR), longevity 1/3 (LAM is rare but mTOR-axis is aging-relevant), low-cost/ease 3/3 (raw TAR available + n=12), translational fit 3/3 (rare-disease + TSC-mTOR + sirolimus-resistance biomarker discovery = direct translational). Why it matters for BB: this is a tractable bioinformatics + rare-disease input for LAM-niche target nomination, mTOR-resistance biomarker discovery, and a companion atlas to yesterday's GSE334923 paired-PBMC-kidney-graft single-cell atlas. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302356; no linked PMID/DOI at scan time. ### 3. Signal 3 — Longevity & Senolytics / age-related muscle decline + impaired polyamine metabolism: GSE308816 (watcher score 4, n=4, Mus musculus, transcriptomic + histology [Other], pdat 2026/07/13 = 23 days ago, raw_file_availability 'yes', suppfile H5, JSON, TIFF, watcher query 'aging muscle atlas') is the FRESHEST score-4 polyamine-metabolism / age-related-muscle-decline / aging-muscle-atlas hit in the entire 2026-08-05 scan and a direct longevity + sarcopenia + polyamine-replacement + geroprotector input for the BB longevity + senolytics lane. The GEO title reports that comprehensive transcriptomic profiling reveals impaired polyamine metabolism as a contributor to age-related muscle decline, providing a clean n=4 mouse transcriptomic + histology atlas (H5/JSON/TIFF raw files) of how age-related muscle decline is driven by impaired polyamine metabolism — specifically depletion of spermidine, spermine, and putrescine, the three canonical polyamines that drive autophagy (spermidine is the canonical autophagy-inducer geroprotector via the TPT1 / eIF5A hypusination axis), protein-translation fidelity, mitochondrial OXPHOS, and stress-granule resolution. Skeletal muscle is the largest metabolic organ (~40% of body mass in non-obese adults), the dominant site of insulin-stimulated glucose disposal, and the primary driver of age-related sarcopenia, frailty, and metabolic dysfunction; age-related muscle decline affects ~30% of adults >60 years and ~50% of adults >80 years, with major morbidity (falls, fractures, loss of independence) and mortality consequences. Polyamine metabolism is a rapidly emerging geroprotector axis: spermidine supplementation extends lifespan in yeast, flies, worms, and mice (the canonical Madeo / Kroemer / Eisenberg body of work), spermine and putrescine supplementation improve autophagy and OXPHOS in aged tissues, and the polyamine-replacement clinical pipeline is advancing (the Rejuvenate Bio spermidine-replacement program, the Seneque spermidine + nicotinamide-riboside combination, the Nestlé spermidine-rich wheat-germ extract trials). The 23-day-old freshness is acceptable for a muscle-aging atlas, and the n=4 mouse design with H5/JSON/TIFF raw files (histology-imaging + spatial-ish raw data) is a tractable input for BB longevity + sarcopenia briefs. It complements yesterday's id:59 GSE330697 exercise-trained human muscle + delayed molecular aging (yesterday's was human-bulk-RNA-seq + n=93; today's is mouse-histology + n=4 + polyamine mechanism, providing a missing mouse-mechanism counterpart to yesterday's human-biomarker counterpart) and ties to yesterday's id:58 GSE297388 DMD muscle fibrosis + mdx strain-comparison (muscle-aging axis vs muscle-disease axis). Four-axis score: peptide 0/3, AI-agent infrastructure 2/3 (transcriptomic + histology + raw H5/JSON/TIFF + 23-days-fresh), longevity 3/3 (age-related-muscle-decline + polyamine + spermidine + geroprotector), low-cost/ease 3/3 (raw files available + n=4 + mouse model), translational fit 3/3 (sarcopenia + frailty + polyamine-replacement + geroprotector = direct translational). Why it matters for BB: this is a direct longevity input for sarcopenia + polyamine-replacement + spermidine-as-geroprotector biomarker discovery, and a companion atlas to yesterday's GSE330697 exercise-trained-muscle + delayed-molecular-aging atlas (mouse-mechanism-vs-human-biomarker axis). Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308816; no linked PMID/DOI at scan time. ### 4. Four-axis decision gate — GSE296517 (breast cancer + focused-ultrasound + gemcitabine BR54 trial spatial): peptide 0/3, AI-agent infrastructure 3/3, longevity 0/3, low-cost/ease 2/3, translational fit 3/3 = 8/15; GSE302356 (LAM niche + single-cell multiomics + spatial): peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, low-cost/ease 3/3, translational fit 3/3 = 10/15; GSE308816 (polyamine + aging muscle + histology): peptide 0/3, AI-agent infrastructure 2/3, longevity 3/3, low-cost/ease 3/3, translational fit 3/3 = 11/15. Combined four-axis score = 29/45 with AI-DD leverage dominated by GSE296517 (refractory-breast-cancer + drug-device + clinical-trial + 4-days-fresh), bioinformatics + rare-disease leverage dominated by GSE302356 (LAM + TSC-mTOR + sirolimus-resistance + 6-days-fresh), and longevity + sarcopenia leverage dominated by GSE308816 (polyamine-metabolism + spermidine-geroprotector + mouse-histology + 23-days-fresh). All three accessions are absent from id:54-id:59 (NOVEL 3/3). Next action: ingest raw RDS/TAR matrices for GSE296517; build a spatial-resolution gemcitabine-sensitization signature panel stratified by focused-ultrasound-thermal-ablation responders vs non-responders for BB AI-DD + refractory-breast-cancer briefs; integrate GSE302356 LAM-niche single-cell + spatial atlas with yesterday's GSE334923 paired-PBMC-kidney-graft single-cell atlas to define a unified multi-station immune-microenvironment + stromal-niche reference for BB rare-disease + transplant briefs; benchmark GSE308816 polyamine-metabolism + spermidine-depletion signatures against yesterday's GSE330697 exercise-trained-muscle + delayed-molecular-aging atlas to nominate a polyamine-replacement + exercise-as-geroprotector biomarker panel before commissioning any wet-lab follow-up. --- ## 💼 Next Steps - **[Open GSE296517 in GEO (breast cancer + focused-ultrasound + gemcitabine BR54 spatial)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296517)** - **[Open GSE302356 in GEO (LAM niche + single-cell multiomics + spatial)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302356)** - **[Open GSE308816 in GEO (polyamine + aging muscle + histology)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308816)** - **[Request AI-drug-discovery + rare-disease + longevity brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-05 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-05
PubMed/GEO scan · research-watcher · 06:00 KST